Easton Hospital, Easton, PA
Sabarina Ramanathan , Sukamal Saha , Suresh Mukkamala , Michael Hicks , Patrick Knight , Daniel Mazzaferro , Thushy Siva , Vinay Bajaj , Lori Hutcherson , Avian Chang , David Livert , Rajen Oza
Background: Unlike in breast cancer or melanoma, resection during sentinel lymph node mapping (SLNM) in colon cancer (CCa) includes regional lymphadenectomy including SLNs and non SLNs. However, SLNM often identifies micrometastases which can be missed by conventional (Conv) surgery and pathologic examination. It is unknown whether this impacts survival or recurrence. Hence, a retrospective analysis was undertaken to study overall (OS) and disease -specific (DSS) survival between patients (pts) undergoing SLNM vs Conv surgery based on the number of +veLNs. Methods: SLNM was done by subserosal injection with blue dye followed by segmental resection including regional lymphadenectomy. All SLNs were ultrastaged and other nodes were examined by conv. methods with H&E. Results: There are 309 pts in SLNM (GpA) vs 499 pts in Conv surgery (GpB); with average no. of lymph nodes (LNs) and +ve LNs 17.3/1.6 vs 14.4/2.49 respectively. For GpA, success rate was 99.6% and the average no of SLN was 3. Of the pts in GpA vs GpB, 1+ve LN were found in 38% vs 27%, 2+ve LNs in 10% vs 16%, and > 2 LNs in 53% vs 57%, respectively. Comparing 5 years OS between GpA vs GpB, for 1+ve LN was 62.8% vs 52.38%, for 2 +ve LNs 72.7% vs 48.65% and for > 2 +ve LNs 35% vs 33.33%, respectively. Similarly, DSS for 1 +veLN was 54.4% vs 47.6%, 2+ve LNs 40% vs 40.54% and > 2+ve LNs, 30.4% vs 25.76%, respectively(Table1.). Conclusions: Compared to Conv surgery, SLNM identified higher no. of LNs per pt with high success rate. Five-year OS and DSS also are better in SLNM vs Conv surgery for all +ve LN gps. Hence, SLNM in CCa may have prognostic value. A larger multicenter trial needs to be done to validate such data.
SLNM(n = 309) Group A | Conventional(n = 499)Group B | p-value | |
---|---|---|---|
Average # of LNs examined | 17.3 | 14.48 | < 0.0001 |
Average # of +ve LNs | 1.6 | 2.49 | |
Average # of SLNs | 3 | N/A | |
Average # of +ve SLNs | 0.6 | N/A | |
SLNM Success Rate | 99.60% | N/A | |
OS | |||
1 +ve node | 62.8% ( n = 43 ) | 52.38 % ( n = 63 ) | 0.288 |
2 +ve nodes | 72.7% ( n = 11) | 48.65% ( n = 37) | 0.189 |
> 2 +ve nodes | 35% (n = 60) | 33.33% ( n = 132) | 0.870 |
DSS | |||
1 +ve node | 54.4% ( n = 46 ) | 47.6 % ( n = 63) | 0.562 |
2 +ve node | 40% (n = 15 ) | 40.54% ( n = 37) | 0.999 |
> 2 +ve nodes | 30.4%(n = 69) | 25.76% ( n = 132) | 0.480 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2017 ASCO Annual Meeting
First Author: Sabarina Ramanathan
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kyung-ha Lee
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Jasleen Kaur Chaddha
2024 ASCO Annual Meeting
First Author: Marwan Alaswad